Seminars in Arthritis and Rheumatism
Volume 40, Issue 1 , Pages 53-72 , August 2010

Laboratory Tests in the Diagnosis and Follow-Up of Pediatric Rheumatic Diseases: An Update

References 

  1. Lane SK, Gravel JW. Clinical utility of common serum rheumatologic tests. Am Fam Physician. 2002;65:1073–1080
  2. Wagner-Weiner L. Laboratory evaluation of children with rheumatic disease. Pediatr Ann. 2002;31:362–371
  3. Shearn MA, Kang IY. Effect of age and sex on the erythrocyte sedimentation rate. J Rheumatol. 1986;13:297–298
  4. Kowalczyk J. Professor Edmund Biernacki (1866-1911) and the discovery of the erythrocyte sedimentation rate. S Afr Med J. 2006;96:40–41
  5. Sox HC, Liang MH. The erythrocyte sedimentation rate. Ann Intern Med. 1986;104:515–523
  6. Paulus HE, Brahn E. Is erythrocyte sedimentation rate the preferable measure of the acute phase response in rheumatoid arthritis?. J Rheumatol. 2004;31:838–840
  7. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–1209
  8. Ravelli A, Martini A. Early predictors of outcome in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2003;21(Suppl 31):S89–S93
  9. Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med. 1930;52:561–571
  10. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol. 2001;38:189–197
  11. Kravitz MS, Pitashny M, Shoenfeld Y. Protective molecules-C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (ApoA1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol. 2005;25:582–591
  12. Gershov D, Kim S, Brot N, Elkon KB. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an anti-inflammatory innate immune response: implications for systemic autoimmunity. J Exp Med. 2000;192:1353–1364
  13. Du Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res. 2004;30:261–277
  14. Szalai AJ. C-reactive protein (CRP) and autoimmune disease: facts and conjectures. Clin Dev Immunol. 2004;11:221–226
  15. Moser KL, Neas BR, Salmon JE, Yu H, Gray-McGuire C, Asundi N, et al. Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. Proc Natl Acad Sci USA. 1998;95:14869–14874
  16. Shai R, Quismorio FP, Li L, Kwon OJ, Morrison J, Wallace DJ, et al. Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families. Hum Mol Genet. 1999;8:639–644
  17. Pulliam PN, Attia MW, Cronan KM. C-reactive protein in febrile children 1 to 36 months of age with clinically undetectable serious bacterial infection. Pediatrics. 2001;108:1275–1279
  18. Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol. 1997;24:1477–1485
  19. Gwither M, Schwarz H, Howard A, Ansell BM. C-reactive protein in juvenile chronic arthritis: an indicator of disease activity and possibly amyloidosis. Ann Rheum Dis. 1982;41:259–262
  20. Wu JF, Yang YH, Wang LC, Lee JH, Shen EY, Chiang BL. Comparative usefulnessof C-reactive protein and erythrocyte sedimentation rate in juvenile rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:782–785
  21. Pepys MB, Lanham JG, De Beer FC. C-reactive protein in SLE. Clin Rheum Dis. 1982;8:91–103
  22. Yeh ET. CRP as a mediator of disease. Circulation. 2004;109(Suppl 1):II11–II14
  23. Tabuchi M, Inoue K, Usui-Kataoka H, Kobayashi K, Teramoto M, Takasugi K, et al. The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res. 2007;48:768–781
  24. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190:1733–1739
  25. Scirè CA, Caporali R, Perotti C, Montecucco C. Plasma procalcitonin in rheumatic diseases. Reumatismo. 2003;55:113–118
  26. Chalumeau M, Leroy S, Gendrel D, Bréart G, Moulin F, Dubos F. Procalcitonin bedside testing in the pediatric emergency department. Arch Pediatr. 2007;14:529–531
  27. Delèvaux I, André M, Colombier M, Albuisson E, Meylheuc F, Bègue RJ, et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes?. Ann Rheum Dis. 2003;62:337–340
  28. Reinhart K, Karzai W, Meisner M. Procalcitonin as a marker of the systemic inflammatory response to infection. Intensive Care Med. 2000;26:1193–1200
  29. Arkader R, Troster EJ, Lopes MR, Júnior RR, Carcillo JA, Leone C, et al. Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome. Arch Dis Child. 2006;91:117–120
  30. Korczowski B, Kowalczyk JR, Bijak M, Rusin J. Concentration of procalcitonin and C-reactive protein in serum and erythrocyte sedimentation rate in active autoimmune diseases in children. Pol Merkur Lekarski. 2003;15:155–157
  31. Fernández Lopez A, Luaces Cubells C, García García JJ, Fernández Pou J Spanish Society of Pediatric Emergencies. Procalcitonin in pediatric emergency departments for the early diagnosis of invasive bacterial infections in febrile infants: results of a multicenter study and utility of a rapid qualitative test for this marker. Pediatr Infect Dis J. 2003;22:895–903
  32. Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum. 1997;40:1250–1256
  33. Butbul-Aviel Y, Koren A, Halevy R, Sakran W. Procalcitonin as a diagnostic aid in osteomyelitis and septic arthritis. Pediatr Emerg Care. 2005;21:828–832
  34. Okada Y, Minakami H, Tomomasa T, Kato M, Inoue Y, Kozawa K, et al. Serum procalcitonin concentration in patients with Kawasaki disease. J Infect. 2004;48:199–205
  35. Catalano-Pons C, André MC, Chalumeau M, Guérin S, Gendrel D. Lack of value of procalcitonin for prediction of coronary aneurysms in Kawasaki disease. Pediatr Infect Dis J. 2007;26:179–180
  36. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 1992;80:1639–1647
  37. Raj DS. Role of inerleukin-6 in the anemia of chronic disease. Semin Arthritis Rheum. 2008;11:[Epub ahead of print]
  38. Rusten LS, Jacobsen SE. Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. Blood. 1995;85:989–996
  39. Means RT, Krantz SB. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest. 1993;91:416–419
  40. Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-α antibody therapy. Blood. 2002;100:474–482
  41. Cazzola M, Ponchio L, de Benedetti F, Ravelli A, Rosti V, Beguin Y, et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood. 1996;87:4824–4830
  42. Means RT, Krantz SB. Inhibition of human erythroid colony-forming units by γ interferon can be corrected by recombinant human erthropoietin. Blood. 1991;78:2564–2567
  43. Schooley JC, Kullgren B, Allison AC. Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anemias. Br J Haematol. 1987;67:11–17
  44. Tzioufas AG, Kokori SI, Petrovas CI, Moutsopoulos HM. Autoantibodies to human recombinant erythropoietin in patients with systemic lupus erythematosus: correlation with anemia. Arthritis Rheum. 1997;40:2212–2216
  45. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med. 1996;334:630–633
  46. Vreugdenhil G, Baltus CA, van Eijk HG, Swaak AJ. Anemia of chronic disease: diagnostic significance of erythrocyte and serological parameters in iron deficient rheumatoid arthritis patients. Br J Rheumatol. 1990;29:105–110
  47. Song JS, Park W, Bae SK, Kim SS, Lee YH, Choi JW, et al. The usefulness of serum trasferrin receptor and ferritin for assessing anemia in rheumatoid arthritis: comparison with bone marrow iron study. Rheumatol Int. 2001;21:24–29
  48. Giannouli S, Voulgarelis M, Ziakas PD, Tzioufas AG. Anemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis. 2006;65:144–148
  49. Voulgarelis M, Kokori SI, Ioannidis JP, Tzioufas AG, Kyriaki D, Moutsopoulos HM. Anemia in systemic lupus erythematosus: aetiological profile and role of erythropoietin. Ann Rheum Dis. 2000;59:217–222
  50. Nossent JC, Swaak AJ. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med. 1991;80:605–612
  51. Yu HH, Wang LC, Lee JH, Lee CC, Yang YH, Chiang BL. Lymphopenia is associated with neuropsychiatric manifestations and disease activity in pediatric systemic lupus erythematosus patients. Rheumatology (Oxford). 2007;46:1492–1494
  52. García Tello A, Villegas Martínez A, González Fernández AF. Hematological abnormalities in patients with systemic lupus erythematosus. Ann Med Interne. 2002;19:539–543
  53. Perrin LH, Lambert PH, Miescher PA. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis. J Clin Invest. 1975;56:165–176
  54. Baqi N, Moazami S, Singh A, Ahmad H, Balachandra S, Tejani A. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol. 1996;7:924–929
  55. Ting CK, Hsieh KH. A long term immunological study of childhood onset systemic lupus erythematosus. Ann Rheum Dis. 1992;51:45–51
  56. Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity. 2007;40:560–566
  57. Ratnoff WD. Inherited deficiencies of complement in rheumatic diseases. Rheum Dis Clin North Am. 1996;22:75–94
  58. Boeckler P, Meyer A, Uring-Lambert B, Goetz J, Cribier B, Hauptmann G, et al. Which complement assays and typings are necessary for the diagnosis of complement deficiency in patients with lupus erythematosus? (A study of 25 patients). Clin Immunol. 2006;121:198–202
  59. Jaskowski TD, Martins TB, Litwin CM, Hill HR. Comparison of three different methods for measuring classical pathway complement activity. Clin Diagn Lab Immunol. 1999;6:137–139
  60. Theil EC. Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms. Ann Rev Biochem. 1987;56:289–315
  61. Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev. 2007;6:457–463
  62. Malope BI, MacPhail AP, Alberts M, Hiss DC. The ratio of serum transferrin receptor and serum ferritin in the diagnosis of iron status. Br J Haematol. 2001;115:84–89
  63. Pelkonen P, Swanljung K, Siimes MA. Ferritinemia as an indicator of systemic disease activity in children with systemic juvenile rheumatoid arthritis. Acta Paediatr Scand. 1986;75:64–68
  64. Beyan E, Beyan C, Demirezer A, Ertuğrul E, Uzuner A. The relationship between serum ferritin levels and disease activity in systemic lupus erythematosus. Scand J Rheumatol. 2003;32:225–228
  65. Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;50:1227–1235
  66. Janka GE. Hemophagocytic syndromes. Blood Rev. 2007;21:245–253
  67. Garcia PC, Longhi F, Branco RC, Piva JP, Lacks D, Tasker RC. Ferritin levels in children with severe sepsis and septic shock. Acta Paediatr. 2007;96:1829–1831
  68. Marhaug G, Dowton SB. Serum amyloid A: an acute phase apolipoprotein and precursor of AA amyloid. Baillieres Clin Rheumatol. 1994;8:553–573
  69. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265:501–523
  70. Koga T, Torigoshi T, Motokawa S, Miyashita T, Maeda Y, Nakamura M, et al. Serum amyloid A-induced IL-6 production by rheumatoid synoviocytes. FEBS Lett. 2008;582:579–585
  71. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem. 1998;35:745–753
  72. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–2371
  73. Pepys MB. Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos Trans R Soc Lond B Biol Sci. 2001;356:203–211
  74. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford). 2002;41:1428–1435
  75. Touitou I, Sarkisian T, Medlej-Hashim M, Tunca M, Livneh A, Cattan D, et al. Country as the primary risk factor for renal amyloidosis in familiar Mediterranean fever. Arthritis Rheum. 2007;56:1706–1712
  76. Mimouni A, Magal N, Stoffman N, Shohat T, Minasian A, Krasnov M, et al. Familial Mediterranean fever: effects of genotype and ethnicity on inflammatory attacks and amyloidosis. Pediatrics. 2000;105:E70
  77. Laxer RM. Pharmacology and drug therapy. In: Textbook of Pediatric Rheumatology. 5th ed.. Philadelphia, PA: Elsevier Saunders; 2005;p. 76–141
  78. Petty RE, Laxer RM. Systemic Lupus Erythematosus. In: Textbook of Pediatric Rheumatology. 5th ed.. Philadelphia, PA: Elsevier Saunders; 2005;p. 342–391
  79. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases (International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases). N Engl J Med. 1992;326:1654–1660
  80. Hoffmann AL, Milman N, Byg KE. Childhood sarcoidosis in Denmark 1979-1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paediatr. 2004;93:30–36
  81. Belfer MH, Stevens RW. Sarcoidosis: a primary care review. Am Fam Physician. 1998;58:2041–20502055-6.
  82. Chesnutt AN. Enigmas in sarcoidosis. West J Med. 1995;162:519–526
  83. Fauroux B, Clément A. Pediatric sarcoidosis. Paediatr Respir Rev. 2005;6:128–133
  84. DeRemee RA. Sarcoidosis. Mayo Clin Proc. 1985;70:177–181
  85. Pachman LM, Hayford JR, Chung A, Daugherty CA, Pallansch MA, Fink CW, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol. 1998;25:1198–1204
  86. Pachman LM. Juvenile dermatomyositis (JDMS): new clues to diagnosis and pathogenesis. Clin Exp Rheumatol. 1994;12:69–73
  87. Suarez CR, Andreeff M, Miller DR. Serum LDH values in childhood acute leukemias and non-Hodgkin's lymphoma. Med Pediatr Oncol. 1984;12:89–92
  88. Sheldon J. Laboratory testing in autoimmune rheumatic diseases. Best Pract Res Clin Rheumatol. 2004;18:249–269
  89. Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol. 2002;55:4–13
  90. Shoenfeld Y, Twig G, Katz U, Sherer Y. Autoantibody explosion in antiphospholipid syndrome. J Autoimmun. 2008;30:74–83
  91. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol. 2002;14:548–552
  92. Hahn RG, Knox LM, Forman TA. Evaluation of poststreptococcal illness. Am Fam Physician. 2005;71:1949–1954
  93. American Academy of Pediatrics, Committee on Infectious Diseases. Group A streptococcal infections. In: The Red Book. Elk Groove Village (IL): American Academy of Pediatrics; 2000;p. 526–536
  94. Hilário MO, Terreri MT. Rheumatic fever and post-streptococcal arthritis. Best Pract Res Clin Rheumatol. 2002;16:481–494
  95. Stollerman G, Lewis AJ, Schultz I, Taranta A. Relationship of immune response to group A streptococci to the course of acute, chronic and recurrent rheumatic fever. Am J Med. 1956;20:163–169
  96. Roodpeyma S, Kamali Z, Zare R. Rheumatic fever: the relationship between clinical manifestations and laboratory tests. J Paediatr Child Health. 2005;41:97–100
  97. Dougados M. Synovial fluid cell analysis. Baillieres Clin Rheumatol. 1996;10:519–534
  98. Pal B, Nash J, Oppenheim B, Dean N, McFarlane L, Maxwell S. Is routine synovial fluid analysis necessary? (Lessons and recommendations from an audit). Rheumatol Int. 1999;18:181–182
  99. Offiah AC. Acute osteomyelitis, septic arthritis and discitis: differences between neonates and older children. Eur J Radiol. 2006;60:221–232
  100. Neogi T, Gladman DD, Ibanez D, Urowitz M. Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J Rheumatol. 2006;33:1785–1788
  101. Von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum. 1995;24:323–358
  102. Malleson PN, Sailer M, Mackinnon MJ. Usefulness of antinuclear antibody testing to screen for rheumatic diseases. Arch Dis Child. 1997;77:299–304
  103. Fenger M, Wiik A, Høier-Madsen M, Lykkegaard JJ, Rozenfeld T, Hansen MS, et al. Detection of antinuclear antibodies by solid-phase immunoassays and immunoflorescence analysis. Clin Chem. 2004;50:2141–2147
  104. Perilloux BC, Shetty AK, Leiva LE, Gedalia A. Antinuclear antibody (ANA) and ANA profile tests in children with autoimmune disorders: a retrospective study. Clin Rheumatol. 2000;19:200–203
  105. Cainelli F, Betterle C, Vento S. Antinuclear antibodies are common in an infectious environment but do not predict systemic lupus erythematosus. Ann Rheum Dis. 2004;63:1707–1708
  106. Deane PM, Liard G, Siegel DM, Baum J. The outcome of children referred to a pediatric rheumatology clinic with a positive antinuclear antibody test but without an autoimmune disease. Pediatrics. 1995;95:892–895
  107. McGhee JL, Kickingbird LM, Jarvis JN. Clinical utility of antinuclear antibody tests in children. BMC Pediatr. 2004;4:13
  108. Woreta F, Thorne JE, Jabs DA, Kedhar SR, Dunn JP. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2007;143:647–655
  109. Ravelli A, Felici E, Magni-Manzoni S, Pistorio A, Novarini C, Bozzola E, et al. Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum. 2005;52:826–832
  110. Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008;152:550–556
  111. Campos LM, Kiss MH, Scheinberg MA, Mangueira CL, Silva CA. Antinucleosome antibodies in patients with juvenile systemic lupus erythematosus. Lupus. 2006;15:496–500
  112. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha. Arthritis Rheum. 2000;43:2383–2390
  113. Day R. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. Lancet. 2002;359:540–541
  114. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus (A long term, prospective study). Arthritis Rheum. 1990;33:634–643
  115. Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol. 2000;53:424–432
  116. Vargas MT, Gustilo K, D'Andrea DM, Kalluri R, Foster MH, Madaio MP. Structural features of nephritogenic lupus autoantibodies. Methods. 1997;11:62–69
  117. van Paassen P, Damoiseaux J, Tervaert JW. Laboratory assessment in musculoskeletal disorders. Best Pract Clin Res Rheumatol. 2003;17:475–494
  118. Houghton K, Malleson P, Cabral D, Petty R, Tucker L. Primary Sjögren's syndrome in children and adolescents: are proposed diagnostic criteria applicable?. J Rheumatol. 2005;32:225–232
  119. Cimaz R, Casadei A, Rose C, Bartunkova J, Sediva A, Falcini F, et al. Primary Sjögren syndrome in the pediatric age: a multicentre survey. Eur J Pediatr. 2003;162:661–665
  120. Brucato A, Frassi M, Franceschini F, Cimaz R, Faden D, Pisoni MP, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum. 2001;44:1832–1835
  121. Gordon P, Khamashta MA, Rosenthal E, Simpson JM, Sharland G, Brucato A, et al. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol. 2004;31:2480–2487
  122. Horsfall AC, Venables PJ, Taylor PV, Maini RN. Ro and La antigens and maternal anti-La idiotype on the surface of myocardial fibres in congenital heart block. J Autoimmun. 1991;4:165–176
  123. Gaudreau A, Amor B, Kahn MF, Ryckewaert A, Sany J, Peltier AP. Clinical significance of antibodies to soluble extractable nuclear antigens (anti-ENA). Ann Rheum Dis. 1978;37:321–327
  124. Martini G, Foeldvari I, Russo R, Cuttica R, Eberhard A, Ravelli A, et al. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 2006;54:3971–3978
  125. Hossny E, Hady HA, Mabrouk R. Anti-centromere antibodies as a marker of Raynaud's phenomenon in pediatric rheumatologic diseases. Pediatr Allergy Immunol. 2000;11:250–255
  126. Kampolis C, Plastiras S, Vlachoyiannopoulos P, Moyssakis I, Tzelepis G. The presence of anti-centromere antibodies may predict progression of estimated pulmonary arterial systolic pressure in systemic sclerosis. Scand J Rheumatol. 2008;37:278–283
  127. Bernstein RM. Autoantibodies in myositis. Baillieres Clin Neurol. 1993;2:599–615
  128. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371:2201–2212
  129. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54:3682–3689
  130. Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford). 2008;47:324–328
  131. Iverson GL. Are antibodies to ribosomal P proteins a clinically useful predictor of neuropsychiatric manifestations in patients with systemic lupus erythematosus?. Lupus. 1996;5:634–635
  132. Press J, Palayew K, Laxer RM, Elkon K, Eddy A, Rakoff D, et al. Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Arthritis Rheum. 1996;39:671–676
  133. Hanly JG. Neuropsychiatric lupus. Rheum Dis Clin North Am. 2005;31:273–298
  134. Wu JF, Yang YH, Wang LC, Lee JH, Shen EY, Chiang BL. Antinucleosome antibodies correlate with the disease severity in children with systemic lupus erythematosus. J Autoimmun. 2007;27:119–124
  135. Su Y, Jia RL, Han L, Li ZG. Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus. Clin Immunol. 2007;122:115–120
  136. Cervera R, Viñas O, Ramos-Casals M, Font J, García-Carrasco M, Sisó A, et al. Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis. 2003;62:431–434
  137. Boren E, Gershwin ME. Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmun Rev. 2004;3:401–406
  138. Thewissen M, Somers V, Venken K, Linsen L, van Paassen P, Geusens P, et al. Analyses of immunosenescent markers in patients with autoimmune disease. Clin Immunol. 2007;123:209–218
  139. Eichenfield AH, Athreya BH, Doughty RA, Cebul RD. Utility of rheumatoid factor in the diagnosis of juvenile rheumatoid arthritis. Pediatrics. 1986;78:480–484
  140. Syed RH, Gilliam BE, Moore TL. Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology. Curr Rheumatol Rep. 2008;10:156–163
  141. Ferucci ED, Majka DS, Parrish LA, Moroldo MB, Ryan M, Passo M, et al. Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2005;52:239–246
  142. Avčin T, Cimaz R, Falcini F, Zulian F, Martini G, Simonini G, et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis. 2002;61:608–611
  143. Low JM, Chauhan AK, Kietz DA, Daud U, Pepmueller PH, Moore TL. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. J Rheumatol. 2004;31:1829–1833
  144. Brunner JK, Sitzmann FC. Anticyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Mod Rheumatol. 2006;16:372–375
  145. de Laat B, Mertens K, de Groot PG. Mechanisms of disease: antiphospholipid antibodies—from clinical association to pathologic mechanisms. Nat Clin Pract Rheumatol. 2008;4:192–199
  146. Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum. 2002;31:256–263
  147. Schultz DR. Antiphospholipid antibodies: basic immunology and assays. Semin Arthritis Rheum. 1997;26:724–739
  148. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet. 1999;353:1348–1353
  149. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—a meta-analysis. Lupus. 1997;6:467–473
  150. Male C, Foulon D, Hoogendoorn H, Vegh P, Silverman E, David M, et al. Predictive value of persistent versus transient antiphopholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood. 2005;106:4152–4158
  151. Nojima J, Iwatani Y, Suehisa E, Kuratsune H, Kanakura Y. The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus. Haematologica. 2006;91:699–702
  152. Kamat AV, D'Cruz DP, Hunt BJ. Managing antiphospholipid antibodies and antiphospholipid syndrome in children. Haematologica. 2006;91:1674–1680
  153. Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol. 1986;41:8–15
  154. Sène D, Piette JC, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev. 2008;7:272–277
  155. Berkun Y, Padeh S, Barash J, Uziel Y, Harel L, Mukamel M, et al. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum. 2006;55:850–855
  156. Kurugöl Z, Vardar F, Özkinay F, Kavakli K, Özkinay C. Lupus anticoagulant and protein S deficiency in otherwise healthy children with acute varicella infection. Acta Paediatr. 2000;89:1186–1189
  157. Manco-Johnson MJ, Nuss R, Key N, Moertel C, Jacobson L, Meech S, et al. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. J Pediatr. 1996;128:319–323
  158. Frauenknecht K, Lackner K, von Landenberg P. Antiphospholipid antibodies in pediatric patients with prolonged activated partial thromboplastin time during infection. Immunobiology. 2005;799–805
  159. Mizumoto H, Maihara T, Hiejima E, Shiota M, Hata A, Seto S, et al. Transient antiphospholipid antibodies associated with acute infections in children: a report of three cases and a review of the literature. Eur J Pediatr. 2006;165:484–488
  160. Conley CL, Hartman RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest. 1952;31:621–622
  161. Pengo V, Ruffatti A. Laboratory diagnosis of antiphospholipid syndrome. Reumatismo. 2007;59:187–191
  162. Harris EN, Boey ML, Mackworth-Young CG, Gharavi AE, Patel BM, Loizou S, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 1983;2:1211–1214
  163. Pierangeli SS, Harris EN. Clinical laboratory testing for the antiphospholipid syndrome. Clin Chim Acta. 2005;357:17–33
  164. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827–1832
  165. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306
  166. Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?. Br Med J. 1982;285:606
  167. Schultz DR, Tozman EC. Antineutrophil cytoplasmic antibodies: major autoantigens, pathophysiology, and disease associations. Semin Arthritis Rheum. 1995;25:143–159
  168. McLaren JS, Stimson RH, McRorie ER, Coia JE, Luqmani RA. The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting. Q J Med. 2001;94:615–621
  169. Šedivá A, Kolářová I, Bartůňková J. Antineutrophil cytoplasmic antibodies in children. Eur J Pediatr. 1998;157:987–991
  170. Bartůňková J, Tesař V, Šedivá A. Diagnostic and pathogenetic role of antineutrophil cytoplasmic autoantibodies. Clin Immunol. 2003;106:73–82
  171. Jennette JC, Wilkman AS, Falk RJ. Diagnostic predictive value of ANCA serology. Kidney Int. 1998;53:796–798
  172. Frosch M, Foell D. Wegener granulomatosis in childhood and adolescence. Eur J Pediatr. 2004;163:425–434
  173. Faure-Fontenla MA, Rodriguez-Suarez RS, Arias-Velasquez R, Garcia-Gonzalez JE. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus in childhood. J Rheumatol. 1999;26:2480–2481
  174. Smith JA, Märker-Hermann E, Colbert RA. Pathogenesis of ankylosing spondylitis: current concepts. Best Pract Res Clin Rheumatol. 2006;20:571–591
  175. Cornélis F. Genetics and clinical practice in rheumatology. Joint Bone Spine. 2003;70:458–464
  176. Thomson W, Donn R. Juvenile idiopathic arthritis genetics—what's new? (What's next?). Arthritis Res. 2002;4:302–306
  177. Prahalad S. Genetics of juvenile idiopathic arthritis: an update. Curr Opin Rheumatol. 2004;16:588–594
  178. Glass DN, Giannini EH. Juvenile rheumatoid arthritis as a complex genetic trait. Arthritis Rheum. 1999;42:2261–2268
  179. Rosen P, Thompson S, Glass D. Non-HLA gene polymorphisms in juvenile rheumatoid arthritis. Clin Exp Rheumatol. 2003;21:650–656
  180. Thomson W, Barrett JH, Donn R, Pepper L, Kennedy LJ, Ollier WE, et al. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology. 2002;41:1183–1189
  181. Zeggini E, Packham J, Donn R, Wordsworth P, Hall A, Thomson W BSPAR Study Group. Association of HLA-DRB1*13 with susceptibility to uveitis in juvenile idiopathic arthritis in two independent data sets. Rheumatology (Oxford). 2006;45:972–974
  182. Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol. 2005;17:586–599
  183. Gattorno M, Martini A. Inherited autoinflammatory syndromes: an expanding new group of chronic inflammatory diseases. Clin Exp Rheumatol. 2005;23:133–136
  184. Brydges S, Kastner DL. The systemic autoinflammatory diseases: inborn errors of the, innate immune system. Curr Top Microbiol Immunol. 2006;305:127–160
  185. Pras E, Aksentijevich I, Gruberg L, Balow JE, Prosen L, Dean M, et al. Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16. N Engl J Med. 1992;326:1509–1513
  186. Gumucio DL, Diaz A, Schaner P, Richards N, Babcock C, Schaller M, et al. Fire and ICE: the role of pyrin domain-containing proteins in inflammation and apoptosis. Clin Exp Rheumatol. 2002;20(Suppl 26):S45–S53
  187. Drenth JP, van der Meer JW. Hereditary periodic fever. N Engl J Med. 2001;345:1748–1757
  188. Majeed HA, El-Khateeb M, El-Shanti H, Rabaiha ZA, Tayeh M, Najib D. The spectrum of familial Mediterranean fever gene mutations in Arabs: report of a large series. Semin Arthritis Rheum. 2005;34:813–818
  189. Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations. Eur J Hum Genet. 2001;9:473–483
  190. Drenth JP, Cuisset L, Grateau G, Vasseur C, van de Velde-Visser SD, de Jong JG, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome (International Hyper-IgD Study Group). Nat Genet. 1999;22:178–181
  191. Hoffman HM, Patel DD. Genomic-based therapy: targeting interleukin-1 for autoinflammatory diseases. Arthritis Rheum. 2004;50:345–349
  192. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor. TNFR1, define a family of dominantly inherited autoinflammatory syndromes Cell. 1999;97:133–144
  193. Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott EM, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore). 2002;81:349–368
  194. Gattorno M, Sormani MP, D'Osualdo A, Pelagatti MA, Caroli F, Federici S, et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum. 2008;58:1823–1832
  195. Ali M, Manolios N. Proteomics in rheumatology: a new direction for old diseases. Semin Arthritis Rheum. 2005;35:67–76

PII: S0049-0172(08)00215-1

doi: 10.1016/j.semarthrit.2008.12.001

Seminars in Arthritis and Rheumatism
Volume 40, Issue 1 , Pages 53-72 , August 2010

Article Tools

* Image Usage & Resolution